About 75%–85% of newly diagnosed bladder cancers are categorized as NMIBC. This type of cancer has a high risk of recurrence and progression into invasive and metastatic cancer . Nadofaragene firadenovec-vncg is the first FDA-approved non-replicating adenoviral vector gene therapy for high-risk NMIBC. The approval was granted based on a clinical trial of 157 patients with high-risk BCG-unresponsive NMIBC.
Study findings Patients received nadofaragene firadenovec-vncg once every three months for up to a year or until the development of unacceptable toxicity to the treatment or recurrence of high-grade NMIBC. 51% of patients achieved a complete response to the treatment and 46% of responding patients displayed complete responses to the treatment for one year. ##Adverse reactions## Bladder discharge Fatigue Bladder spasm Urinary urgency Hematuria Chills Fever Painful urination ##…
